Experimental investigation of esophageal reconstruction with electrospun polyurethane nanofiber and 3D printing polycaprolactone scaffolds using a rat model.
Park H., Kim IG., Wu Y., Cho H., Shin JW., Park SA.
Animal Study with a reported sample of 7, published in Head Neck (2020) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Head Neck (2020)
- Country
- United States
- Reported sample size
- 7
- Source database
- PubMed
- PMID
- 33241663
- DOI
- 10.1002/hed.26540
Abstract (original English)
We evaluated the outcome of esophageal reconstructions using tissue-engineered scaffolds. Partial esophageal defects were reconstructed with the following scaffolds; animals were grouped (n = 7 per group) as follows: (a) normal rats; (b) rats implanted with three-dimensional printing (3DP) polycaprolactone (PCL) scaffolds; (c) with human adipose-derived mesenchymal stem cell (ADSC)-seeded 3DP PCL scaffolds; (d) with polyurethane (PU)-nanofiber(Nf) scaffolds; and (e) with ADSC-seeded PU-Nf scaffolds. The esophageal defects were successfully repaired; however, muscle regeneration was greater in the 3DP PCL + ADSC groups than in the PU-Nf + ADSC groups (P < .001). Regeneration of the epithelium was greater in PU-Nf and PU-Nf + ADSC groups than in the 3DP PCL and 3DP PCL + ADSC groups (P < .001). A tendency for more re-epithelization was observed with the PU-Nf scaffolds, while more muscle regeneration was achieved with the 3DP PCL scaffolds.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.